You are here: Industry Insights > Horizon Discovery

News List

PerkinElmer to Acquire Cell Engineering Company Horizon Discovery americanpharmaceuticalreview
November 06, 2020
PerkinElmer and Horizon Discovery Group have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire Horizon for approximately $383 million (£296 million).
PerkinElmer to Acquire Horizon Discovery americanpharmaceuticalreview
November 04, 2020
PerkinElmer and Horizon Discovery Group have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire Horizon for approximately $383 million.
Rentschler, Horizon Ink Cell Line Development Pact contractpharma
May 20, 2020
The alliance aims to drive efficiencies in biotherapeutic manufacturing from early drug development through commercial manufacturing.
Novel micro-RNA therapeutic hits early targets in ischemic heart diseases pharmatimes
April 02, 2020
Horizon Discovery has announced positive early-stage results for a novel micro-RNA therapeutic for ischemic heart diseases.
Horizon Discovery Partners for Target Identification contractpharma
August 29, 2018
Horizon Discovery Group has entered into a collaboration with a global pharma partner to co-develop and apply a novel cutting-edge research tool for target identification and validation.
Abcam ends pursuit of £270M Horizon Discovery buyout fiercebiotech
May 10, 2018
Even without taking over Horizon, Abcam could still seek to satisfy its “strong interest in pursuing strategic expansion in the gene editing market” through some other means. (Abcam)
Horizon Discovery releases CHO genome sequence to drive innovation in bioproduction pharmaasia
August 16, 2017
This high value reference tool enables the industry to screen for genes associated with desired phenotypes and to help drive innovation in bioproduction.
ATUM and Horizon Discovery announce collaboration pharmaasia
June 13, 2017
Horizon’s CHO SOURCE Platform now incorporates exclusive ATUM vectors as standard
Horizon Discovery introduces four BRAF resistant melanoma PDX models pharmaasia
June 08, 2017
PDX models of tumors offer better in vivo insights for cancer research and drug development. These highly characterized models were originally exclusively licensed from The Wistar Insitute